Cytochrome P450-Mediated Cardiovascular Drug Interactions

Heart Disease

Volumn 2, Issue 3, 2000, Pages 254-258

  Cheng, Judy W M ^a,b,c  

^a LONG ISLAND UNIVERSITY   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; CYTOCHROME P 450 ENZYME SYSTEM; CYTOCHROME P450;

CARDIOVASCULAR DISEASE; DRUG INTERACTION; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMAN;

EID: 0034189835     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Gonzalez FJ. Molecular genetics of the P-450 superfamily. Pharmac Ther 1990; 45:1-38.
2. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995;29:619-24.
3. Guengerich FP, Dannan GA, Wright ST, Marin MV, Kaminsky LS. Purification and characterization of liver microsomal cytochrome P450: electrophoretic, spectral, catalytic and immunochemical properties and inducibility of eight isozymes isolated from rats treated with phenobarbital or B-naphthoflavone. Biochemistry 1982;21:6019-6030.
4. Waxman DJ, Walsh C. Phenobarbital-induced rat liver cytochrome P-450-purification and characterization of two closely related isozymic forms. J Biol Chem 1982;2257:10446-10457.
5. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18(1):84-112.
6. Heimark LD, Wienkers L, Dunze K, Gibaldi M, Eddy AC, Trager WF, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clin Pharmacol Ther 1992;51:398-407.
7. Slaughter RL, Edwards DJ. Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 1995;29:619-624.
8. Shinn AF. Clinical relevance of cimetidine drug interactions. Drug Safety 1992; 7;245-267.
9. Levy RH. Cytochrome P450 isoenzyme and anticpileptic drug interactions. Epilepsia 1995;36(suppl 5):S8-13.
10. Venkatesan K. Pharmacokinetic drug interactions with rifampin. Clin Pharmacokinet 1992;22:47-65.
11. Spinler S, Cheng JWM, Kindwall KE, Charland SL. Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther 1995;57: 89-94.
12. Nolan PE Jr, Marcus FL, Karol MD, Hoyer GL, Gear K. Effect of phenytoin on the clinical pharmacokinetics of amiodarone. J Clin Pharmacol 1990;30:1112-1119.
13. Gore JM, Haffajee CI, Alpert JS. Interaction of amiodarone and dipheylhydantoin. Am J Caraiol 1984;54:1145.
14. Marcus FI. Drug interactions with amiodarone. Am Heart J 1983;106:924-930.
15. Saal AK, Werner JA, Greene HL, Sears GR, Graham EL. Effect of amiodarone on serum quinidine and procainamide levels. Am J Cardiol 1984;53:1264-1267.
16. DeVane CL, Gill HS, Markowitz JS, Carson WH. Awareness of potential drug interactions may aid avoidance. Ther Drug Monit 1997;19:366-367.
17. Fuhr U, Dummert AL. The fate of naringin in humans: a key to grapefruit juice-drug interactions. Clin Pharmacol Ther 1995;58:364-373.
18. Abramowicz M, ed. Grapefruit juice interactions with drugs. Med Lett 1995;37: 63-64.
19. Leidholm NH. Erythromycin-felodipine interaction [letter]. Drug Intell Clin Pharm 1991;25:1007-1008.
20. Jalava KM, Olkkola KT, Neuvonen PJ. Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 1997;61:410-415.
21. Fromm MF, Busse D, Kroemer HK, Eichelbaum M. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996; 24:796-801.
22. Bradford RH, Shear CL, Chremos AN, Dujovne C, Downton M, Franklin FA, et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991;151:43-49.
23. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994;16:366-385.
24. Ayanian JZ, Ruchs CS, Stone RM. Lovastatin and rhabdomyolysis [letter]. Ann Intern Med 1988;109:682-683.
25. Garnett WR. Interactions with hydroxymethyglutaryl-coenzyme A reductase inhibitor. Am J Health-Syst Pharm 1995;52:1639-1645.
26. Kunze KL, Wienkers LC, Thummel KH, Trater WF. Warfarin-fluconazole. I. Inhibition of human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 1996;24:422-428.
27. Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, et al. Warfarin-fluconazole. II. A metabolically based drug interaction: in vitro studies. Drug Metab Dispos 1996;24:422-428.
28. Gillum JG, Isreal DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993;25:450-482.
29. Oberg KC. Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy. Pharmacotherapy 1998;18(2):386-391.
30. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985;89:1235-1241.
31. Nemeroff CB, DeVane L, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320.
32. Brosen K. Are pharmacokinetic drug interactions with SSRIs an issue? Int Clin Psychopharmacol 1996;11(suppl 1):23-27.
33. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J, Cantilena LR. Torsades de pointes occurring in association with terfenadine use. JAMA 1990; 264:2788-2790.
34. Honig PK, Woosley RL, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-1518.
35. Kivisto KT, Neuvonen PJ, Klotz U. Inhibition of terfenadine metabolism: pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokinet 1994; 7:1-5.
36. Oberg K, Bauman JL. QT interval prolongation and Torsades de pointes due to crythromycin lactobionate. Pharmacotherapy 1995;15:687-692.
37. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52:213-218.
38. Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995;29:906-917.
39. Inman W, Kubota K. Tachycardia during cisapride treatment. Br Med J 1992; 305:748-749.
40. Bran S, Murray W, Hirsch IB, Plamer JP. Long QT syndrome during high-dose cisapride. Arch Intern Med 1995;155:765-768.
41. Wysowski DK, Bacsanyi J. Cisapride and fatal arrhythmia. N Engl J Med 1996; 335:290-291.
42. Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337:268-269.
43. Bailey DG, Arnold JMO, Munoz C, Spence JD. Grapefruit juice-felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther 1993;53:637-642.
44. Merkel U, Sigusch H, Hoffman A. Grapefruit juice inhibits 7-hydroxylation of coumarin in healthy volunteers. Eur J Clin Pharmacol 1994;46:175-177.